Patents Assigned to ViRexx Medical Corp.
  • Publication number: 20090238822
    Abstract: Disclosed herein are chimeric antigens, comprising an hepatitis C virus (HCV) antigen and a Fc fragment of an immunoglobulin for eliciting an immune response against said antigen. The immune response is enhanced by presenting the host immune system with an immune response domain (HCV antigen from HCV core, envelope, or non-structural protein fragments) and a target binding domain (an Fc fragment). By virtue of the target binding domain, antigen presenting cells internalize and process the chimeric antigens for antigen presentation, thereby eliciting both a humoral and cellular immune response.
    Type: Application
    Filed: October 13, 2006
    Publication date: September 24, 2009
    Applicant: VIREXX MEDICAL CORP.
    Inventors: Rajan George, Lorne Tyrrell, Antoine A. Noujaim, Bruce Darryl Hirsche, Dakun Wang, Allan Ma, Bruce Motyka
  • Publication number: 20080160063
    Abstract: The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks; the solid-phase agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the rapid formation of a platelet-mediated thrombus about the solid-phase agent causing vessel occlusion.
    Type: Application
    Filed: October 30, 2007
    Publication date: July 3, 2008
    Applicant: VIREXX MEDICAL CORP.
    Inventors: Michael W. Stewart, Antoine Noujiam, Roland H. Person
  • Patent number: 7390488
    Abstract: The present invention relates generally to methods and compositions for targeting, delivering, and activating platelet-dependent vascular occlusion agents. In particular, antibodies carrying platelet binding agents are targeted to hyperplastic cells or tissues, such as the vasculature of solid tumor masses; the platelet binding agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the formation of a platelet-mediated thrombus-causing vessel occlusion.
    Type: Grant
    Filed: August 17, 2005
    Date of Patent: June 24, 2008
    Assignee: ViRexx Medical Corp.
    Inventors: Michael W. Stewart, Antoine Noujaim, Roland H. Person
  • Publication number: 20050031628
    Abstract: Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular, the compounds and methods elicit immune responses against foreign antigens that are otherwise recognized by the host as “self” antigens, thus breaking host tolerance to those antigens. Presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises an antibody fragment, enhances the immune response against the foreign or tolerated antigen. Antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response against the desired antigen.
    Type: Application
    Filed: August 5, 2004
    Publication date: February 10, 2005
    Applicant: ViRexx Medical Corp.
    Inventors: Rajan George, Lorne Tyrrell, Antoine Noujaim, Dakun Wang, Allan Ma
  • Publication number: 20050013828
    Abstract: Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular embodiments, the compounds and methods elicit immune responses against antigens that are otherwise recognized by the host as “self” antigens. The immune response is enhanced by presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises a xenotypic antibody fragment. By virtue of the target binding domain, antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response.
    Type: Application
    Filed: August 5, 2004
    Publication date: January 20, 2005
    Applicant: ViRexx Medical Corp.
    Inventors: Rajan George, Lorne Tyrrell, Antoine Noujaim, Dakun Wang, Allan Ma